In a recent industry webinar organized by Standard BioTools, Dr. Barbara Breznik shared groundbreaking insights into glioblastoma (GBM) research using targeted expression profiling on patient-derived samples sourced from Gliobank. Her team’s work sheds light on biomarkers associated with poor prognosis and therapy resistance, paving the way for more effective treatment strategies.

Key Highlights from the Webinar:

• How targeted gene expression profiling using the Standard BioTools™ Biomark™ system uncovered novel biomarkers linked to patient prognosis
• Insights into distinct molecular signatures across tumor regions highlighting the complexity of GBM and its invasive behavior
• How patient-derived organoids replicate treatment-induced DNA damage responses for translational model development